Clinical Pharmacokinetics

, Volume 36, Issue 4, pp 277–287 | Cite as

Clinical Pharmacokinetics and Pharmacodynamics of Buspirone, an Anxiolytic Drug

Review Articles Drug Disposition

Abstract

Buspirone is an anxiolytic drug given at a dosage of 15 mg/day. The mechanism of action of the drug is not well characterised, but it may exert its effect by acting on the dopaminergic system in the central nervous system or by binding to serotonin (5-hydroxytryptamine) receptors. Following a oral dose of buspirone 20mg, the drug is rapidly absorbed. The mean peak plasma concentration (Cmax) is approximately 2.5 μg/L, and the time to reach the peak is under 1 hour. The absolute bioavailability of buspirone is approximately 4%.

Buspirone is extensively metabolised. One of the major metabolites of buspirone is 1-pyrimidinylpiperazine (1-PP), which may contribute to the pharmacological activity of buspirone.

Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg, an elimination half-life of about 2.5 hours and the pharmacokinetics are linear over the dose range 10 to 40mg.

After multiple-dose administration of buspirone 10 mg/day for 9 days, there was no accumulation of either parent compound or metabolite (1-PP). Administration with food increased the Cmax and area under the plasma concentration-time curve (AUC) of buspirone 2-fold.

After a single 20mg dose, the Cmax and AUC increased 2-fold in patients with renal impairment as compared with healthy volunteers. The Cmax and AUC were 15-fold higher for the same dose in patients with hepatic impairment compared with healthy individuals. The half-life of buspirone in patients with hepatic impairment was twice that in healthy individuals. The pharmacokinetics of buspirone were not affected by age or gender.

Coadministration of buspirone with verapamil, diltiazem, erythromycin and itraconazole substantially increased the plasma concentration of buspirone, whereas Cimetidine and alprazolam had negligible effects. Rifampicin (rifampin) decreased the plasma concentrations of buspirone almost 10-fold.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Riblet LA, Eison SA, Eison MS, et al. Neuropharmacology of buspirone. Psychopharmacology 1984; 17 Suppl. 3: 69–78.Google Scholar
  2. 2.
    Temple DL, Yevich JP, New JS. Buspirone: chemical profile of a new class of anxioselective agents. J Clin Psychiatry 1982; 43: 4–9.PubMedGoogle Scholar
  3. 3.
    Cimino M, Ponzio F, Achilli G, et al. Dopaminergic effects of buspirone, a novel anxiolytic agent. Biochem Pharmacol 1983; 32: 1069–74.PubMedCrossRefGoogle Scholar
  4. 4.
    Glaser T, Traber J. Buspirone: action on serotonin receptors in calf hippocampus. Eur J Pharmacol 1983; 88: 137–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Berlin I, Chalon S, Payan C, et al. Evaluation of the α2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects: relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)piperazine. Br J Clin Pharmacol 1995; 39: 243–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Oakley NR, Jones BJ. Buspirone enhances [3H]flunitrazepam binding in vivo. Eur J Pharmacol 1983; 87: 499–500.PubMedCrossRefGoogle Scholar
  7. 7.
    Kristjansson F. Sensitive determination of buspirone in serum by solid phase extraction and two dimensional high performance liquid chromatography. J Chromatogr 1991; 566: 250–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Tsai TH, Chen CF. Measurement and pharmacokinetic analysis of buspirone by means of brain microdialysis coupled to high performance liquid chromatography with electrochemical detection. J Chromatogr 1997; 762: 269–73.CrossRefGoogle Scholar
  9. 9.
    Bianchi G, Caccia S. Simultaneous determination of buspirone, gepirone, ipsapirone and their common metabolite 1-(2-pyrimidinyl)piperazine in rat plasma and brain by high performance liquid chromatography. J Chromatogr 1988; 431: 477–80.PubMedCrossRefGoogle Scholar
  10. 10.
    Odontiadis J, Franklin M. Simultaneous quantitation of buspirone and its major metabolite 1-(2-pyrimidinyl)piperazine in human plasma by high performance liquid chromatography with coulometric detection. J Pharm Biomed Anal 1996; 14: 347–51.PubMedCrossRefGoogle Scholar
  11. 11.
    Sciacca MA, Duncan GF, Shea JP, et al. Simultaneous quantitation of buspirone and 1-(2-pyrimidinyl)piperazine in human plasma and urine by capillary gas chromatography mass spectrometry. J Chromatogr 1988; 428: 265–74.PubMedCrossRefGoogle Scholar
  12. 12.
    Gaillard Y, Gay Montchamp JP, Ollagnier M. Simultaneous screening and quantitation of alpidem, Zolpidem, buspirone and benzodiazepines by dual channel gas chromatography using electron capture and nitrogen phosphorus detection after solid phase extraction. J Chromatogr 1993; 622: 97–208.Google Scholar
  13. 13.
    Betto P, Meneguz A, Ricciarello G, et al. Simultaneous high performance liquid chromatographic analysis of buspirone and its metabolite 1-(2 pyrimidinyl)-piperazine in plasma using electrochemical detection. J Chromatogr 1992; 575: 17–21.Google Scholar
  14. 14.
    Kerns EH, Bullen WW, Gammans RE. Quantitative analysis of 1-(2-pyrimidinyl)piperazine in plasma by capillary gas chromatography mass spectrometry. J Chromatogr 1986; 377: 195–203.PubMedCrossRefGoogle Scholar
  15. 15.
    Gammans RE, Kerns EH, Bullen WW. Capillary gas chromatographic mass spectrometric determination of buspirone in plasma. J Chromatogr 1985; 345: 285–97.PubMedCrossRefGoogle Scholar
  16. 16.
    Goldthwaite Jr CA, Hsieh FY, Womble SW, et al. Liquid chromatography/chemical reaction interface mass spectrometry as an alternative to radioisotopes for quantitative drug metabolism studies. Anal Chem 1996; 68: 2996–3001.PubMedCrossRefGoogle Scholar
  17. 17.
    Mayol RF, Adamson DS, Gammans RE, et al. Pharmacokinetics and disposition of 14C-buspirone HCl after intravenous and oral dosing in man [abstract]. Clin Pharmacol Ther 1985; 37: 210.Google Scholar
  18. 18.
    Jajoo HK, Mayol RF, LaBudde JA, et al. Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab Disp 1989; 17: 634–40.Google Scholar
  19. 19.
    Gammans RE, Mayol RF, Eison ME. Concentration of buspirone and 1-pyrimidinylpiperazine, a metabolite in rat brain [abstract]. Fed Proc 1983; 42: 377.Google Scholar
  20. 20.
    Bullen WW, Bivens DL, Gammans RE, et al. The binding of buspirone to human plasma proteins [abstract]. Fed Proc 1985; 44: 1123.Google Scholar
  21. 21.
    Gammans RE, Mayol RF, Mackenthun AV, et al. The relationship between buspirone bioavailability and dose in healthy subjects. Biopharm Drug Disp 1985; 6: 139–45.CrossRefGoogle Scholar
  22. 22.
    Barbhaiya RH, Shukla UA, Pfeffer M, et al. Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses. Eur J Clin Pharmacol 1994; 46: 41–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Mayol RF, Gammans RE, Mackenthun AV, Sokya LF. The effect of food on the bioavailability of buspirone HCl [abstract]. Clin Res 1983; 31: 631A.Google Scholar
  24. 24.
    Caccia S, Vigano GL, Mingardi G, et al. Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. Clin Pharmacokinet 1988; 14: 171–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Dalhoff K, Poulsen HE, Garred P, et al. Buspirone pharmacokinetics in patients with cirrhosis. Br J Clin Pharmacol 1987; 24: 547–50.PubMedCrossRefGoogle Scholar
  26. 26.
    Gammans RE, Mayol RF, LaBudde JA. Metabolism and disposition of buspirone. Am J Med 1986; 80 Suppl. 3B: 41–51.PubMedCrossRefGoogle Scholar
  27. 27.
    Lamberg TS, Kivisto KT, Neuvonen PJ. Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone. Clin Pharmacol Ther 1998; 63: 640–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Kivisto KT, Lamberg TS, Kantola T, et al. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther 1997; 62: 348–54.PubMedCrossRefGoogle Scholar
  29. 29.
    Erwin CW, Linnoila M, Hartwell J, et al. Effects of buspirone and diazepam, alone and in combination with alcohol, on skilled performance and evoked potentials. J Clin Psychopharmacol 1986; 6: 199–209.PubMedCrossRefGoogle Scholar
  30. 30.
    Ashton CH, Rawlins MD, Tyrer SP. A double blind placebo controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. Br J Psychiatry 1990; 157: 232–8.PubMedCrossRefGoogle Scholar
  31. 31.
    van Laar MW, Volkerts ER, van Willigenburg AR Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients. J Clin Psychopharmacol 1992; 12: 86–95.PubMedGoogle Scholar
  32. 32.
    Gammans RE, Pfeffer M, Westrick ML, et al. Lack of interaction between Cimetidine and buspirone. Pharmacotherapy 1987; 7: 72–9.PubMedGoogle Scholar
  33. 33.
    Ciraulo DA, Barnhill JG, Ciraulo AM, et al. Alterations in pharmacodynamics of anxiolytics in abstinent alcoholic men: subjective responses, abuse liability, and electroencephalographic effects of alprazolam, diazepam, and buspirone. J Clin Pharmacol 1997; 37: 64–73.PubMedCrossRefGoogle Scholar
  34. 34.
    Lamberg TS, Kivisto KT, Neuvonen PJ. Concentrations and effects of buspirone are considerably reduced by rifampicin. Br J Clin Pharmacol 1998; 45: 381–5.PubMedCrossRefGoogle Scholar
  35. 35.
    Buch AB, Van Harken DR, Seidehamel RJ, et al. A study of pharmacokinetic interaction between buspirone and alprazolam at steady state. J Clin Pharmacol 1993; 33: 1104–9.PubMedGoogle Scholar
  36. 36.
    Huang HF, Jann MW, Wei FC, et al. Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia. J Clin Pharmacol 1996; 36: 963–9.PubMedGoogle Scholar
  37. 37.
    Olkkhola VA, Neuvonen PJ. Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clin Pharmacol Ther 1996; 59: 369–75.CrossRefGoogle Scholar
  38. 38.
    Backman JT, Olkkola KT, Aranko K, et al. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 1994; 37: 221–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Schlanz KD, Myre SA, Bottorff MB. Pharmacokinetic interactions with calcium channel antagonists: Part I. Clin Pharmacokinet 1991; 21: 344–56.PubMedCrossRefGoogle Scholar
  40. 40.
    Schlanz KD, Myre SA, Bottorff MB. Pharmacokinetic interactions with calcium channel antagonists: Part II. Clin Pharmacokinet 1991; 21: 448–60.PubMedCrossRefGoogle Scholar
  41. 41.
    Lilja JJ, Kivisto KT, Backman JT, et al. Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther 1998; 64: 655–60.PubMedCrossRefGoogle Scholar
  42. 42.
    Kolars JC, Schmiedline-Ren P, Schuetz JD, et al. Identification of rifampicin-induced P450IIIA (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992; 90: 1871–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Dawson GW, Jue SG, Brogden RN. Alprazolam: a review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression. Drugs 1984; 11: 132–47.CrossRefGoogle Scholar
  44. 44.
    Sethy VH, Harris DW. Determination of biological activity of alprazolam, triazolam and their metabolites. J Pharm Pharmacol 1982; 34: 115–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Desmond PV, Patwardhan RW, Schenkar S, et al. Cimetidine impairs elimination of chlordiazepoxide in man. Ann Intern Med 1980; 93: 266–8.PubMedGoogle Scholar
  46. 46.
    Klotz U, Reimann I. Delayed clearance of diazepam due to Cimetidine. N Engl J Med 1980; 302: 1012–4.PubMedCrossRefGoogle Scholar
  47. 47.
    Goff DC, Midha KK, Brotman AW, et al. An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 1991; 11: 193–7.PubMedGoogle Scholar
  48. 48.
    Kivisto KT, Lamberg TS, Neuvonen PJ. Interactions of buspirone with itraconazole and rifampicin: effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone. Pharmacol Toxicol 1999; 84: 94–7.PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  1. 1.Division of Pharmaceutical Evaluation I, Food and Drug Administration, Room 4079, Woodmont Office Center IIOffice of Clinical Pharmacology and Biopharmaceutics (HFD-860)RockvilleUSA

Personalised recommendations